Related Experiment Videos
Variants of the CYP11B2 gene predict response to therapy with candesartan
Jan R Ortlepp1, Peter Hanrath, Vera Mevissen
1Medical Clinic I, University Hospital of Aachen, Pauwelsstrasse 30, 52057 Aachen, Germany. jrortlepp@ukaachen.de
Abstract:
In a prospective trial, patients with an elevated diastolic blood pressure (above 95 mm Hg) received high-dose (16 mg) or low-dose (8 mg) candesartan in addition to standardised medication. A positive response to treatment was defined as a diastolic blood pressure <85 mm Hg at follow-up. Genotyping for two candidate genes was performed in 116 patients. Genotypes of the CYP11B2 promotor polymorphism significantly predicted a positive response to treatment (CC: 67%; TC: 34%; TT: 21%; p=0.005).
Insights
This study found that the CYP11B2 gene polymorphism influences treatment response in patients with high blood pressure. Specific genotypes predicted the effectiveness of candesartan medication.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Genetics
Background:
- Elevated diastolic blood pressure (hypertension) is a significant cardiovascular risk factor.
- Standardized medication and high-dose (16 mg) or low-dose (8 mg) candesartan were used in a prospective trial.
- Treatment success was defined as achieving a diastolic blood pressure below 85 mm Hg.
Purpose of the Study:
- To investigate the role of candidate gene polymorphisms in predicting response to candesartan treatment.
- To analyze the association between CYP11B2 promotor polymorphism and treatment outcomes in hypertensive patients.
Main Methods:
- A prospective trial involving 116 patients with elevated diastolic blood pressure.
- Patients received either high-dose or low-dose candesartan alongside standardized medication.
- Genotyping was performed for two candidate genes, focusing on the CYP11B2 promotor polymorphism.
Main Results:
- The CYP11B2 promotor polymorphism significantly predicted a positive treatment response.
- Genotype frequencies and response rates were: CC (67%), TC (34%), and TT (21%).
- A p-value of 0.005 indicated statistical significance for this association.
Conclusions:
- CYP11B2 gene polymorphism is a significant predictor of candesartan treatment efficacy in hypertensive patients.
- Genetic profiling may help personalize hypertension treatment strategies.
- Further research is warranted to explore the clinical utility of CYP11B2 genotyping in managing hypertension.